Curaleaf Holdings (CURLF) Common Equity (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Common Equity of $69.8 million for Q1 2026, up 214.31% year-on-year from $22.2 million in Q1 2025, and down 90.77% on a QoQ basis from $756.3 million in Q4 2025.
Curaleaf Holdings (CURLF) Common Equity (2019 - 2026) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Common Equity for 8 consecutive years, with $69.8 million the latest figure, recorded in Q1 2026.
- Quarterly Common Equity rose 214.31% year-over-year to $69.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.8 million (up 214.31% YoY) and the FY2025 annual result came in at $756.3 million, down 12.18% from the prior year.
- Common Equity declined to $69.8 million in Q1 2026 per CURLF's latest filing, from $756.3 million in the prior quarter.
- Over the last five years, Common Equity for CURLF reached as high as $1805.5 billion in Q1 2022 and fell as low as -$171.3 million in Q3 2025.
- A 5-year average of $106.9 billion and a median of $958.9 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity jumped 112316.97% — and 2025, when it slumped 117.86%.
- Year by year, Common Equity stood at $1.3 billion in 2022, then dropped by 17.9% to $1.1 billion in 2023, then fell by 18.03% to $861.2 million in 2024, then decreased by 12.18% to $756.3 million in 2025, then plunged by 90.77% to $69.8 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $69.8 million, $756.3 million, and -$171.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | 69.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.80 Mn |
| Dec 31, 2025 | 756.35 Mn |
| Sep 30, 2025 | -171.25 Mn |
| Jun 30, 2025 | -114.22 Mn |
| Mar 31, 2025 | -61.06 Mn |
| Dec 31, 2024 | 861.21 Mn |
| Sep 30, 2024 | 958.92 Mn |
| Jun 30, 2024 | 992.84 Mn |
| Mar 31, 2024 | -48.31 Mn |
| Dec 31, 2023 | 1.05 Bn |
| Sep 30, 2023 | 1.09 Bn |
| Jun 30, 2023 | 1.18 Bn |
| Mar 31, 2023 | -54.38 Mn |
| Dec 31, 2022 | 1.28 Bn |
| Sep 30, 2022 | 1.71 Bn |
| Jun 30, 2022 | 1.78 Bn |
| Mar 31, 2022 | 1,805.54 Bn |
| Dec 31, 2021 | 1.55 Bn |
| Sep 30, 2021 | 1.76 Bn |
| Jun 30, 2021 | 1.81 Bn |